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Abstract
A recent RNAi screen used a genome-wide shRNA library to search for cellular factors required
for HIV-1 replication. This work complements three other siRNA-based screening studies and
potentially opens the door to the discovery of factors that are important for HIV-1 replication in
physiological host cells such as T lymphocytes. shRNA screens can be further improved, and they
could promise to unravel new pathways and new facets of virus-cell interactions.
Commentary
The advent of RNAi-based whole-genome screens in
mammalian cells provides a new impetus to the search of
host cell factors needed for HIV replication [1,2]. Three
screens that used siRNA pools to identify cellular proteins
important in HIV-1 replication were reported in 2008,
and a meta-analysis of these studies has been published
recently [3-6]. One shortcoming to these reported screens
is the use of HeLa or HEK293T cells that are not physio-
logical substrates for infection by HIV-1. In addition, the
use of a pseudotyped virus or a mutated strain of HIV-1
also limits the interpretability of some of the results. With
this backdrop, a recently published genome-wide shRNA-
screening performed in Jurkat T lymphocytes for cellular
genes that contribute to HIV-1 replication (Figure 1)
advances the field by extending the functional screening
for cellular factors from attached epithelial/fibroblast cells
to suspension T-cells [7].
In the shRNA loss-of-function screen, Jurkat cells are
transduced with a lentiviral vector-based shRNA library.
The lentivector is derived from feline immunodeficiency
virus and is pseudotyped with the vesicular stomatitis
virus G protein. A major advantage that makes this
scheme attractive is its potential application to cells that
can be physiologically infected by HIV-1, including pri-
mary T cells and macrophages. In addition, it is notewor-
thy that the transduced Jurkat cells have been selected for
shRNA-expression for extended duration before being
subject to HIV-1 infection. This pre-infection selection for
shRNA-expression serves to eliminate those shRNA-cell
clones which are silenced for a gene whose knock down
dramatically affects cell growth or survival. The pre-selec-
tion procedure thus significantly reduces the number of
false positive genes identified in the screening. Unlike siR-
NAs, the activity of shRNAs in the cell is not transient, but
is long-lasting. Because shRNAs are stably expressed,
infection of cell clones with HIV-1 can be initiated at any
desired time. Thus, HIV-1 infection can be performed
long after the shRNA has silenced transcripts coding for
long-lived proteins; these long half-life proteins generally
cannot be depleted efficiently by transiently-transfected
siRNAs. For the above reasons, shRNA screens have cer-
tain inherent and nuanced advantages over siRNA screens
in selected settings.
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the search for HIV-1 replication cofactors appears to be far
from saturated. Overlaps among the genes identified in
the four screens are scarce [7]; and some well known HIV-
1 cofactors such as the Sp1 transcription factor, which
drives LTR-dependent expression of viral genes, were not
identified [6]. This lends credence to the notion that the
approaches were not exhaustive. The goal of siRNA and
shRNA screens is to identify all possible HIV-1 cofactors.
For productive replication to occur, HIV-1 has to switch
on and off many cellular pathways. Plausibly, at different
stages of infection HIV-1 would hijack different cofactors
to modulate the same cellular function for its own benefit.
Thus, even an essential cofactor could become non-essen-
tial in a different experimental context (e. g., at an exceed-
ingly high multiplicity of infection). That is to say, the
quantitative differences in critical assay parameters such
as multiplicity and duration of infection might actually
affect the qualitative outcomes of a siRNA or shRNA
screen. In addition, off-target effects, differences in cell
types and differences in how the primary data sets are fil-
tered have also been suggested to account for the identifi-
cation of the many different HIV-1 cofactors in the screens
[1].
In the shRNA screen of Yeung et al., although the removal
of cell clones that did not survive puromycin selection
helped to reduce the number of false positive genes whose
loss would globally inhibit cell growth or survival, rather
than specifically affect HIV-1 replication, this step which
eliminated more than 80% of the transduced cell clones
might falsely miss those HIV-1 cofactors that are also
simultaneously important for cell growth and/or survival.
This issue has to be addressed in future screens. Thus, as
the search continues, many more HIV-1 cofactors from
different cell types are likely to emerge from further tar-
geted si-/sh-RNA screens. Collectively, the four initial
RNAi screens have already implicated new pathways that
were not known previously to play critical roles in HIV-1
replication [8]. For example, HIV-1 cofactors have been
identified as components of the mediator complex that
regulates transcription [9], the nuclear pore complex that
regulates macromolecular entry and egress, and the Golgi
apparatus that specifies protein processing. While the
mediator complex is thought to support Tat-dependent
transcriptional activation of HIV-1 long terminal repeats
(LTR), the nucleoporins and Golgi proteins could be crit-
ically involved in the intracellular transport and process-
ing of viral nucleic acids and proteins (Table 1). Given the
wide ranging functions of host cofactors identified in the
four screens, the jury is still out as to which newly identi-
fied factors are of preeminence in the HIV-1 life cycle. As
mentioned above, it would not be surprising that depend-
ing on the cell type and the experimental context, different
cellular factors may be implicated as being rate-determin-
ing for HIV-1 replication. For example, the identification
of different nucleoporins in different screens suggests that
HIV-1 might employ different components of the nuclear
pore complex to facilitate nuclear import/export of viral
nucleic acids and proteins under different circumstances.
HIV-1 infection has been suggested to exert a suppressive
effect on miRNA processing and RNA-silencing [10-16].
Indeed, the forced overexpression of shRNA and siRNA in
cells might also have the potential to exhaust the cellular
machinery for RNA silencing [17], complicating the inter-
pretation of biological outcomes. Whether these influ-
ences might significantly affect the siRNA and shRNA
screens for HIV-1 cofactors remains to be determined. We
note, however, that the expression of a single shRNA from
a lentiviral vector is unlikely to overwhelm the cell's RNAi
machinery. Moreover, when shRNA-cell clones are
infected by HIV-1, the shRNA-silencing of targeted
mRNAs would have already been completed and would
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activities.
One important direction for improving the shRNA
approach is to use inducible expression systems to express
the shRNAs. In this regard, a deoxycycline-inducible retro-
viral vector has already been used successfully to construct
a shRNA expression library [18]. Inducible expression of
shRNAs might also help overcome potential adaptation
by the cell to shRNAs, and the premature elimination of
many shRNA-expressing cell clones. A further improve-
ment to control for the possibility that some HIV-1 cofac-
tors might also be required for the full expression of the
feline immunodeficiency virus derived lentiviral vector
would be to use alternate expression formats such as ade-
noviral vectors.
The technology of shRNA-based screening is still in its
infancy [19,20]. These early reports of siRNA/shRNA
screens for HIV-1 replication cofactors are therefore not
the beginning of the end, but the end of the beginning of
a new era in the search for host factors required for HIV-1
replication. Future screens will improve the stringency of
the selection, expand upon the cell types being analyzed,
and devise better strategies to address false positive/nega-
tive candidates. Furthermore, more specific questions in
HIV-1 life cycle might also be addressed with siRNA and
shRNA screens. For example, screens can be used to iden-
tify all the cofactors required for a specific process in HIV-
1 replication such as fusion, viral entry, Tat-dependent
transcription or integration. Synthetic lethal screens may
also be employed to shed light on the functional interac-
tion between different cofactors. In the years to come, the
four recently reported complementary siRNA and shRNA
approaches will likely be regarded as setting an important
milestone for our understanding of host cell – HIV-1
interaction.
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